Status:
COMPLETED
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
Lead Sponsor:
Teva Neuroscience, Inc.
Conditions:
Parkinson's Disease
Eligibility:
All Genders
35+ years
Phase:
PHASE3
Brief Summary
Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
Eligibility Criteria
Inclusion
- Men and women with Parkinson's disease (PD) whose diagnosis is confirmed by at least two of the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without other known or suspected cause of parkinsonism.
- Subjects must be age 35 years or older.
- Subjects not taking or requiring anti-parkinsonian medications, except for anticholinergics.
Exclusion
- Subjects with unstable systemic medical problems or clinically significant malignancy, with particular attention to clinically significant or unstable vascular disease
Key Trial Info
Start Date :
July 1 1997
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2000
Estimated Enrollment :
404 Patients enrolled
Trial Details
Trial ID
NCT00203060
Start Date
July 1 1997
End Date
July 1 2000
Last Update
April 12 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.